109 related articles for article (PubMed ID: 30998672)
1. Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women - United States, 2008 and 2016.
McClung NM; Gargano JW; Park IU; Whitney E; Abdullah N; Ehlers S; Bennett NM; Scahill M; Niccolai LM; Brackney M; Griffin MR; Pemmaraju M; Querec TD; Cleveland AA; Unger ER; Markowitz LE;
MMWR Morb Mortal Wkly Rep; 2019 Apr; 68(15):337-343. PubMed ID: 30998672
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.
Silverberg MJ; Leyden WA; Lam JO; Gregorich SE; Huchko MJ; Kulasingam S; Kuppermann M; Smith-McCune KK; Sawaya GF
Lancet Child Adolesc Health; 2018 Oct; 2(10):707-714. PubMed ID: 30236379
[TBL] [Abstract][Full Text] [Related]
3. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012.
Hariri S; Bennett NM; Niccolai LM; Schafer S; Park IU; Bloch KC; Unger ER; Whitney E; Julian P; Scahill MW; Abdullah N; Levine D; Johnson ML; Steinau M; Markowitz LE;
Vaccine; 2015 Mar; 33(13):1608-13. PubMed ID: 25681664
[TBL] [Abstract][Full Text] [Related]
4. Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States.
Hariri S; Johnson ML; Bennett NM; Bauer HM; Park IU; Schafer S; Niccolai LM; Unger ER; Markowitz LE;
Cancer; 2015 Aug; 121(16):2775-81. PubMed ID: 26098295
[TBL] [Abstract][Full Text] [Related]
5. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.
McClung NM; Gargano JW; Bennett NM; Niccolai LM; Abdullah N; Griffin MR; Park IU; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):602-609. PubMed ID: 30792242
[TBL] [Abstract][Full Text] [Related]
6. Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008-2015.
Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Johnson Jones ML; Whitney E; Pemmaraju M; Brackney M; Abdullah N; Scahill M; Dahl RM; Cleveland AA; Unger ER; Markowitz LE;
Clin Infect Dis; 2019 Apr; 68(8):1282-1291. PubMed ID: 30137283
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States.
Saadeh K; Park I; Gargano JW; Whitney E; Querec TD; Hurley L; Silverberg M
Vaccine; 2020 Jan; 38(1):39-45. PubMed ID: 31611099
[TBL] [Abstract][Full Text] [Related]
8. HPV type-specific trends in cervical precancers in the United States, 2008 to 2016.
Gargano JW; McClung N; Lewis RM; Park IU; Whitney E; Castilho JL; Pemmaraju M; Niccolai LM; Brackney M; DeBess E; Ehlers S; Bennett NM; Scahill M; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
Int J Cancer; 2023 Jan; 152(2):137-150. PubMed ID: 35904861
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of 1, 2, and 3 Doses of Human Papillomavirus Vaccine Against High-Grade Cervical Lesions Positive for Human Papillomavirus 16 or 18.
Johnson Jones ML; Gargano JW; Powell M; Park IU; Niccolai LM; Bennett NM; Griffin MR; Querec T; Unger ER; Markowitz LE;
Am J Epidemiol; 2020 Apr; 189(4):265-276. PubMed ID: 31680146
[TBL] [Abstract][Full Text] [Related]
10. Declines in Human Papillomavirus (HPV)-Associated High-Grade Cervical Lesions After Introduction of HPV Vaccines in Connecticut, United States, 2008-2015.
Niccolai LM; Meek JI; Brackney M; Hadler JL; Sosa LE; Weinberger DM
Clin Infect Dis; 2017 Sep; 65(6):884-889. PubMed ID: 28520854
[TBL] [Abstract][Full Text] [Related]
11. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
12. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions.
Powell SE; Hariri S; Steinau M; Bauer HM; Bennett NM; Bloch KC; Niccolai LM; Schafer S; Unger ER; Markowitz LE
Vaccine; 2012 Dec; 31(1):109-13. PubMed ID: 23137842
[TBL] [Abstract][Full Text] [Related]
13. Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia.
Hall MT; Simms KT; Lew JB; Smith MA; Saville M; Canfell K
PLoS One; 2018; 13(2):e0185332. PubMed ID: 29444073
[TBL] [Abstract][Full Text] [Related]
14. Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008-2012.
Hariri S; Markowitz LE; Bennett NM; Niccolai LM; Schafer S; Bloch K; Park IU; Scahill MW; Julian P; Abdullah N; Levine D; Whitney E; Unger ER; Steinau M; Bauer HM; Meek J; Hadler J; Sosa L; Powell SE; Johnson ML;
Emerg Infect Dis; 2015 Sep; 21(9):1557-61. PubMed ID: 26291379
[TBL] [Abstract][Full Text] [Related]
15. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study.
Herweijer E; Sundström K; Ploner A; Uhnoo I; Sparén P; Arnheim-Dahlström L
Int J Cancer; 2016 Jun; 138(12):2867-74. PubMed ID: 26856527
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
17. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program.
Baldur-Felskov B; Dehlendorff C; Junge J; Munk C; Kjaer SK
Cancer Causes Control; 2014 Jul; 25(7):915-22. PubMed ID: 24797870
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer.
Joste NE; Ronnett BM; Hunt WC; Pearse A; Langsfeld E; Leete T; Jaramillo M; Stoler MH; Castle PE; Wheeler CM;
Cancer Epidemiol Biomarkers Prev; 2015 Jan; 24(1):230-40. PubMed ID: 25363635
[TBL] [Abstract][Full Text] [Related]
19. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
Riethmuller D; Jacquard AC; Lacau St Guily J; Aubin F; Carcopino X; Pradat P; Dahlab A; Prétet JL
BMC Public Health; 2015 May; 15():453. PubMed ID: 25934423
[TBL] [Abstract][Full Text] [Related]
20. Assessing Impact of HPV Vaccination on Cervical Cancer Incidence among Women Aged 15-29 Years in the United States, 1999-2017: An Ecologic Study.
Mix JM; Van Dyne EA; Saraiya M; Hallowell BD; Thomas CC
Cancer Epidemiol Biomarkers Prev; 2021 Jan; 30(1):30-37. PubMed ID: 33082207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
